Table 2.

Randomized studies comparing single vs tandem ASCT

StudyFirst ASCTConsolidation s/p first ASCTMaintenanceEFSOSSalvage ASCT at relapse
IFM9454  MEL140 + TBI (single arm) None vs MEL140 + TBI Interferon α Median EFS: 25 (single) vs 30 (tandem) mo (P = .03) Median OS: 48 (single) vs 58 (tandem) mo (P = .01) 22% (single arm) vs 26% (tandem arm) 
MEL140 (tandem arm) 
Bologna 7655  MEL200 None vs MEL120 + busulfan Interferon α Median EFS: 23 (single) vs 25 (tandem) mo (P = .001) 7-y OS: 46% (single) vs 43% (tandem) (P = .9) 33% (single arm) vs 10% (tandem arm) 
GMMG-HD213  MEL200 None vs second ASCT with MEL200 Interferon α Median EFS: 25 (single) vs 28.7 (tandem) mo (P = .53) Median OS: 73 (single) vs 75.3 (tandem) mo (P = .33) 26% (single arm) vs 24% (tandem arm) 
BMT CTN 0702 (NCT01109004) MEL200 None vs RVD ×4 vs second ASCT with MEL200 Len until progression for all arms Not yet reported Not yet reported Not yet reported 
StudyFirst ASCTConsolidation s/p first ASCTMaintenanceEFSOSSalvage ASCT at relapse
IFM9454  MEL140 + TBI (single arm) None vs MEL140 + TBI Interferon α Median EFS: 25 (single) vs 30 (tandem) mo (P = .03) Median OS: 48 (single) vs 58 (tandem) mo (P = .01) 22% (single arm) vs 26% (tandem arm) 
MEL140 (tandem arm) 
Bologna 7655  MEL200 None vs MEL120 + busulfan Interferon α Median EFS: 23 (single) vs 25 (tandem) mo (P = .001) 7-y OS: 46% (single) vs 43% (tandem) (P = .9) 33% (single arm) vs 10% (tandem arm) 
GMMG-HD213  MEL200 None vs second ASCT with MEL200 Interferon α Median EFS: 25 (single) vs 28.7 (tandem) mo (P = .53) Median OS: 73 (single) vs 75.3 (tandem) mo (P = .33) 26% (single arm) vs 24% (tandem arm) 
BMT CTN 0702 (NCT01109004) MEL200 None vs RVD ×4 vs second ASCT with MEL200 Len until progression for all arms Not yet reported Not yet reported Not yet reported 

s/p, status-post; TBI, total body irradiation.

Close Modal

or Create an Account

Close Modal
Close Modal